{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:22:10Z","timestamp":1760908930262},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T00:00:00Z","timestamp":1431648000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00432-015-1984-4","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T07:24:19Z","timestamp":1431588259000},"page":"2013-2022","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma"],"prefix":"10.1007","volume":"141","author":[{"given":"Wolfram","family":"Poenisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Pl\u00f6tze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Holzvogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Andrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schliwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zehrfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maik","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz Albert","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Kreibich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Gutsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kolja","family":"Reifenrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidrun","family":"Schwarzbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Leiblein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thoralf","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifa-Katrin","family":"AlAli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,15]]},"reference":[{"key":"1984_CR1","unstructured":"Altekruse SF, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W (2011) SEER cancer statistics review 1975\u20132007, National Cancer Institute, Bethesda. http:\/\/www.seercancergov\/csr\/1975-2007 . Accessed March 10, 2011"},{"key":"1984_CR2","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood.V122.21.3193.3193","volume":"122","author":"JG Berdeja","year":"2013","unstructured":"Berdeja JG, Savona MR, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn IW (2013) Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood 122:3193","journal-title":"Blood"},{"key":"1984_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","volume":"160","author":"JR Berenson","year":"2013","unstructured":"Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321\u2013330","journal-title":"Br J Haematol"},{"key":"1984_CR4","first-page":"846","volume":"87","author":"M Boccadoro","year":"2002","unstructured":"Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, Rus C, Bertola A, Giaccone L, Omede P, Musto P, Pileri A (2002) Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 87:846\u2013850","journal-title":"Haematologica"},{"key":"1984_CR5","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/sj.leu.2404661","volume":"21","author":"I Breitkreutz","year":"2007","unstructured":"Breitkreutz I, Lokhorst HM, Raab MS, van der Holt B, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IGH, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H (2007) Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 21:1294\u20131299","journal-title":"Leukemia"},{"key":"1984_CR6","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V114.22.2679.2679","volume":"114","author":"CA Burchardt","year":"2009","unstructured":"Burchardt CA, Brugger W, Maschmeyer G, Kofahl-Krause D, Fischer L, Roller F, Barth J, Rummel MJ (2009) Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III Study of B-R vs. CHOP-R (NHL 1-2003 trial) of the Stil (Study group indolent Lymphomas, Germany). Blood 114:2679","journal-title":"Blood"},{"key":"1984_CR7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376:2075\u20132085","journal-title":"Lancet"},{"key":"1984_CR8","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Garthon G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BGM, San Miguel J, Lonial S, International Myeloma Working Group (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 117:6063\u20136073","journal-title":"Blood."},{"key":"1984_CR9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1701461","volume":"22","author":"R Clark","year":"1998","unstructured":"Clark R, Brammer C (1998) Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 22:859\u2013863","journal-title":"Bone Marrow Transplant"},{"key":"1984_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","volume":"9","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M (2009a) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302\u2013306","journal-title":"Clin Lymphoma Myeloma"},{"key":"1984_CR11","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","volume":"27","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF (2009b) VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086\u20136093","journal-title":"J Clin Oncol"},{"key":"1984_CR12","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J-P, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau J-L, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Gavo M, Rajkumar SV, Durie BGM, Miguel JS (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976\u20134984","journal-title":"J Clin Oncol"},{"key":"1984_CR13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842\u2013854","journal-title":"Cancer"},{"key":"1984_CR14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"1984_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","volume":"98","author":"H Goldschmidt","year":"1997","unstructured":"Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R (1997) Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 98:736\u2013744","journal-title":"Br J Haematol"},{"key":"1984_CR16","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","volume":"27","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27:5720\u20135726","journal-title":"J Clin Oncol"},{"key":"1984_CR17","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3324\/haematol.10759","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546\u2013549","journal-title":"Haematologica"},{"key":"1984_CR18","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","volume":"119","author":"S Kumar","year":"2012","unstructured":"Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Raikumar SV (2012) Randomized, multicenter phase 2 study (EVOLUTION) of combination of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:4375\u20134382","journal-title":"Blood"},{"key":"1984_CR19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","volume":"166","author":"M Leiba","year":"2014","unstructured":"Leiba M, Kedmi M, Duek A, Freidman T, Weiss M, Leiba R, Nagler A, Avigdor A (2014) Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD)-based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol 166:702\u2013710","journal-title":"Br J Haematol"},{"key":"1984_CR20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"1984_CR21","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","volume":"123","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weissmann A, Adam Z (2014) Bendamustine-bortezomib-dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985\u2013991","journal-title":"Blood"},{"key":"1984_CR22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood.V122.21.2155.2155","volume":"122","author":"M-V Mateos","year":"2013","unstructured":"Mateos M-V, Oriol A, Rosinol L, de Arriba F, Martin J, Martinez-Lopez J, Echeveste MA, Sarra J, Ramirez G, Ocio EM, Martinez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea A, Blade J, Lahuerta JJ, San Miguel JF (2013) Phase 2 study of bendamustine, bortezomib (velcade) and prednisone (BVP) For newly diagnosed multiple myeloma. Blood 122:2155","journal-title":"Blood"},{"key":"1984_CR23","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","volume":"118","author":"P Moreau","year":"2011","unstructured":"Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pegourie B, Kolb B, Stoppa AM, Fuzibet J, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traulle C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau J (2011) Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 118:5752\u20135758","journal-title":"Blood"},{"key":"1984_CR24","unstructured":"Offidani M, Corvatta L, Maracci L, Liberati AM, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P, Olivieri A, Leoni P (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: a phase II study. Blood Cancer J 22(3):e162. doi: 10.1038\/bcl.2013.58"},{"issue":"5","key":"1984_CR25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2009.22.7561","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Guiliani N, Petrucci MT, Must P, Liberati AM, Rossi G, Corradini P, Boccadoro M (2010) Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 28(5):800\u2013807","journal-title":"J Clin Oncol"},{"key":"1984_CR26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"W P\u00f6nisch","year":"2006","unstructured":"P\u00f6nisch W, Mitrou PS, Merkle K-H, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014a randomized phase III study of the East German Study Group of Haematology and Oncology (OSHO). J Cancer Res Clin Oncol 132:205\u2013212","journal-title":"J Cancer Res Clin Oncol"},{"key":"1984_CR27","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood.V118.21.1933.1933","volume":"118","author":"W P\u00f6nisch","year":"2011","unstructured":"P\u00f6nisch W, Wiesler J, Wagner I, Leiblein S, Edel E, Al-Ali HK, Vucinic V, Hegenbart U, Hei\u00df C, Niederwieser D, Goldschmidt H (2011) Impact of bendamustine pretreatment on stem cell mobilization and autologous stem cell transplantation in patients with multiple myeloma. Blood 118:1933","journal-title":"Blood"},{"key":"1984_CR28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00432-012-1212-4","volume":"138","author":"W P\u00f6nisch","year":"2012","unstructured":"P\u00f6nisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed\/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405\u20131412","journal-title":"J Cancer Res Clin Oncol"},{"key":"1984_CR29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-012-1339-3","volume":"139","author":"W P\u00f6nisch","year":"2013","unstructured":"P\u00f6nisch W, Bourgeois M, Moll B, Heyn S, J\u00e4kel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, A\u00dfmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Sch\u00f6nfelder U, Zehrfeld T, Hensel G, L\u00f6schcke K, Krahl R, AL-Ali H, Niederwieser D (2013) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499\u2013508","journal-title":"J Cancer Res Clin Oncol"},{"key":"1984_CR30","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00432-014-1737-9","volume":"140","author":"W P\u00f6nisch","year":"2014","unstructured":"P\u00f6nisch W, Holzvogt B, Pl\u00f6tze M, Andrea M, Bourgeois M, Heyn S, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann F-A, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Winkelmann C, Krahl R, Remane Y, Hennig E, Schliwa Lindner T, Kaiser T, Vucinic V, Behre G, Niederwieser D (2014) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed\/untreated multiple myeloma. J Cancer Res Clin Oncol 140:1947\u20131956","journal-title":"J Cancer Res Clin Oncol"},{"key":"1984_CR31","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VHJ, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase 2 clinical trial. Leukemia 23:1337\u20131341","journal-title":"Leukemia"},{"key":"1984_CR32","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"116","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, DeLaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679\u2013686","journal-title":"Blood"},{"key":"1984_CR33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosi\u00f1ol","year":"2012","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, Hern\u00e1ndez D, L\u00f3pez-Jim\u00e9nez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonz\u00e1lez Y, Etxebeste MA, D\u00edaz-Mediavilla J, Hern\u00e1ndez MT, de Arriba F, Guti\u00e9rrez NC, Mart\u00edn-Ramos ML, Cibeira MT, Mateos MV, Mart\u00ednez J, Alegre A, Lahuerta JJ, San Miguel J, Blad\u00e9 J, Programa para el Estudio y la Terap\u00e9utica de las Hemopat\u00edas Malignas, Grupo Espa\u00f1ol de Mieloma (PETHEMA, GEM) group (2012) Superiority of bortezomib, thalidomide, dexamethasone (VTD) as induction pretranplantations therapy in multiple myeloma: a randomized phase III PETHEMA\/GEM study. Blood 120:1589\u20131596","journal-title":"Blood"},{"key":"1984_CR34","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T, Avet-Loiseau H, Attal M (2014) Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the intergroupe francophone du myelome. J Clin Oncol 32:2712\u20132717","journal-title":"J Clin Oncol"},{"issue":"24","key":"1984_CR35","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 30(24):2946\u20132955","journal-title":"J Clin Oncol"},{"issue":"26","key":"1984_CR36","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","volume":"31","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Goldschmidt H, Rosi\u00f1ol L, Blade J, Lahueerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine D, Moreau P (2013) Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 31(26):3279\u20133287","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1984-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-1984-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1984-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T04:59:23Z","timestamp":1599022763000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-1984-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-1984-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,15]]}}}